GSK bonuses cut by China bribery investigation

GlaxoSmithKline has cut the bonus of its chief executive Andrew Witty following China’s bribery investigation of the pharmaceutical company. In its 2013 annual report, the company said: “The ongoing investigation by authorities in China was also considered by the committee.

Get unlimited access to all Global Investigations Review content